Marginally failed study for Europe [Study As­sess­ment]

posted by balakotu – India, 2018-04-24 09:30 (2191 d 12:40 ago) – Posting: # 18726
Views: 4,098

Hi,
I have conducted a full replicate BE study for one of the highly variable product for Europe regulatory.
Based on the reference product variability, relaxed 90% Confidence Intervals is 75.18 to 133.01 for Cmax.
Study marginally failed with 90% upper CI data of 133.18
Is there any way to justify Europe regulatory authority(ies) to accept this study data? (DCP submission)

Regards


Edit: Category changed; see also this post #1 and #4. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,653 registered users;
67 visitors (1 registered, 66 guests [including 7 identified bots]).
Forum time: 22:11 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5